Skip to content

GSK plans to buy Canada#39;s Bellus Health for $2 billion to expand on respiratory therapies

The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC)

Read More

​ The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC) The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC)  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish